Catheter Precision Inc. (NYSE American: VTAK) stands out as a key player in medical technology, renowned for its groundbreaking cardiac electrophysiology products, VIVO™and LockeT. The rapid growth of the medical technology sector in recent years has caught the attention of investors, leading them to explore companies within this industry. 

On April 24, Catheter Precision made headlines by securing a purchase order from HCA Healthcare Inc. (NYSE: HCA) for the LockeT product. This milestone is significant for Catheter Precision as HCA Healthcare is a top-tier healthcare services provider in the U.S., with a massive revenue of $64 billion in 2023. HCA Healthcare operates 186 hospitals across 2,400 care sites in 20 U.S. states and the United Kingdom. The potential inclusion of additional prestigious academic institutions in the near to mid-term should not be unexpected. 

Catheter Precision, Inc. (NYSE American: VTAK) surged by 26.18% to $0.58 on April 24, 2024, with trading volume at 8.5x the average. It closed above key moving averages (10-, 20-, 50-, and 200-day DMA’s), which signals a strong upward trend and entering breakout territory. These positive trends, along with multiple bullish indicators, highlight VTAK as a stock worth monitoring closely.  Catheter Precision, Inc. (NYSE American: VTAK) was highlighted in a Ladenburg Thalmann research report on April 5, 2023, with a buy recommendation and a $4 target price for the next year.

David Jenkins, states "We have acquired fresh insights from contacts within management circles, leading us to anticipate the addition of esteemed academic institutions in the near to mid-term." Additionally,

Jerkins, highlighted the significance of receiving the purchase order from HCA Healthcare, emphasizing HCA's value-conscious approach. Approval within HCA's healthcare system is a notable achievement, demonstrating recognition of LockeT's value by healthcare professionals. The purchase order, from an HCA-affiliated regional medical center, suggests potential usage of up to 1,000 devices yearly across various specialties. Investors may find it worthwhile to monitor Catheter Precision's stock following this development.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com